COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Financial Forecast | Analyst price targets range from $12 to $60, with projections of peak revenues reaching $2.3 billion for COMP360 across global markets and indications |
Market Momentum | Explore the evolving landscape of psychedelic therapeutics and Compass Pathways' position at the forefront of a potentially transformative approach to mental health care |
Trial Tribulations | Delve into the challenges and opportunities of Compass Pathways' Phase III trials, including recruitment hurdles and the anticipated data release in Q4 2024 |
Psilocybin Pionee | Compass Pathways leads the charge in psychedelic therapeutics, developing COMP360 for treatment-resistant depression with a potential billion-dollar market |
Metrics to compare | CMPS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCMPSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.3x | −2.0x | −0.6x | |
PEG Ratio | 0.09 | 0.04 | 0.00 | |
Price / Book | 14.5x | 3.8x | 2.6x | |
Price / LTM Sales | - | 8.2x | 3.3x | |
Upside (Analyst Target) | 158.5% | 349.0% | 40.3% | |
Fair Value Upside | Unlock | 9.5% | 4.5% | Unlock |